\-\ Texto\\:\\ \ \(0\)\
\-\ firm\\,\\ tender\\ mass\\ of\\ the\\ posterior\\ right\\ knee\\.\ \(0\)\
\-\ normal\\ cbc\\,\\ metabolic\\ panel\\,\\ and\\ liver\\ enzymes\\.\ \(0\)\
\-\ mass\\ was\\ surgically\\ resected\\ with\\ no\\ further\\ evidence\\ of\\ metastasis\\ on\\ follow\\-up\\ studies\\.\ \(0\)\
\-\ radiographs\\:\\ \\ large\\ mass\\ with\\ well\\ defined\\ margins\\ emanating\\ from\\ posterior\\ cortex\\ of\\ the\\ distal\\ right\\ femur\\.\\ \\ radiolucent\\ line\\,\\ visible\\ on\\ the\\ lateral\\ radiograph\\ separates\\ tumor\\ from\\ cortex\\ \\.\ \(0\)\
\-\ mri\\:\\ \\ posterior\\ cortical\\ surface\\ distal\\ femoral\\ diaphysis\\ mass\\,\\ 7\\.3cm\\ x\\ 6\\.7cm\\ x\\ 8\\.3cm\\,\\ with\\ heterogeneous\\ signal\\ intensity\\.\\ \\ on\\ t1\\-weighted\\ mr\\ image\\ shows\\ a\\ heterogenously\\ low\\ signal\\ intensity\\ mass\\ signal\\.\\ t2\\-weighted\\ mr\\ image\\ shows\\ a\\ well\\-defined\\ parosteal\\ mass\\ juxtaposed\\ to\\ the\\ cortex\\ with\\ heterogenous\\ high\\ signal\\ intensity\\ mass\\ posterior\\ to\\ it\\.\\ \\ t2\\ post\\ gadolinium\\ study\\ shows\\ low\\ signal\\ intensity\\ in\\ posterior\\ mass\\ correlating\\ with\\ high\\ signal\\ intensity\\ region\\ on\\ t2\\ image\\ consistent\\ with\\ necrosis\\.\\ \\ ossification\\ center\\ at\\ base\\ of\\ mass\\ adjacent\\ to\\ cortical\\ bone\\.\\ \\ no\\ popliteal\\ vessel\\ invasion\\,\\ no\\ adjacent\\ soft\\ tissue\\ invasion\\.\\ \\ no\\ femoral\\ distant\\ metastasis\\.\ \(0\)\
\-\ parosteal\\ osteosarcoma\ \(9\)\
\-\ parosteal\\ osteosarcoma\\,\\ juxtacortical\\ \\ myositis\\ ossificans\\,\\ sessile\\ osteochondroma\\,\\ periosteal\\ osteosarcoma\ \(0\)\
\-\ 24\\ y\\/o\\ male\\ with\\ right\\ posterior\\ knee\\ mass\ \(1\)\
\-\ parosteal\\ osteosarcomas\\ are\\ uncommon\\ malignant\\ bone\\ tumors\\ that\\ account\\ for\\ approximately\\ 3\\%\\ of\\ osteosarcomas\\.\\ \\ they\\ occur\\ in\\ adults\\ between\\ the\\ 2nd\\ and\\ 5th\\ decades\\ and\\ affect\\ both\\ males\\ and\\ females\\ equally\\.\\ \\ they\\ typically\\ present\\ with\\ insidious\\ onset\\ of\\ symptoms\\ of\\ pain\\,\\ swelling\\,\\ and\\ a\\ palpable\\ mass\\.\\ \\ the\\ large\\ size\\ of\\ many\\ of\\ these\\ tumors\\ on\\ presentation\\ is\\ due\\ to\\ a\\ delay\\ in\\ the\\ patient\\ consulting\\ a\\ physician\\ because\\ of\\ the\\ slow\\ onset\\ of\\ symptoms\\.\\ \\ parosteal\\ osteosarcomas\\ occur\\ nearly\\ exclusively\\ in\\ long\\ tubular\\ bones\\,\\ most\\ commonly\\ in\\ the\\ femur\\,\\ which\\ accounts\\ for\\ 65\\%\\ of\\ cases\\.\\ \\ in\\ this\\ bone\\,\\ they\\ typically\\ arise\\ on\\ the\\ posterior\\ surface\\ of\\ the\\ distal\\ femur\\ in\\ the\\ metaphyseal\\ region\\.\ \(0\)\
\-\ on\\ plain\\ radiographs\\,\\ parosteal\\ osteosarcomas\\ appear\\ as\\ a\\ large\\ radiodense\\,\\ oval\\ or\\ spheroid\\ mass\\ with\\ smooth\\ lobulated\\ or\\ irregular\\ margins\\,\\ attached\\ in\\ a\\ sessile\\ manner\\ to\\ a\\ possibly\\ thickened\\ external\\ cortex\\.\\ \\ a\\ thin\\ radiolucent\\ line\\ or\\ cleavage\\ plane\\ separates\\ the\\ tumor\\ from\\ the\\ underlying\\ bone\\ and\\ is\\ caused\\ by\\ a\\ 2\\-3mm\\ fibrous\\ membrane\\.\\ \\ as\\ the\\ lesion\\ grows\\ in\\ size\\,\\ the\\ radiolucent\\ line\\ is\\ obscured\\ by\\ the\\ tumor\\ growing\\ circumferentially\\ around\\ the\\ bone\\.\ \(0\)\
\-\ ossification\\ of\\ the\\ tumor\\ extends\\ from\\ the\\ base\\ of\\ the\\ lesion\\ to\\ its\\ periphery\\ in\\ contrast\\ to\\ myositis\\ ossificans\\,\\ which\\,\\ when\\ mature\\,\\ shows\\ a\\ zonal\\ pattern\\ with\\ peripheral\\ ossification\\.\ \(0\)\
\-\ on\\ ct\\ images\\,\\ foci\\ of\\ radiolucencies\\ in\\ the\\ superficial\\ parts\\ of\\ the\\ tumor\\ may\\ represent\\ low\\-grade\\ malignant\\ cartilaginous\\,\\ fibrous\\ tissue\\,\\ or\\ entrapped\\ fat\\ and\\ trabeculae\\,\\ whereas\\,\\ more\\ central\\ radiolucencies\\ may\\ correlate\\ with\\ high\\-grade\\ dedifferentiated\\ tumor\\.\ \(0\)\
\-\ mri\\ should\\ be\\ done\\ to\\ evaluate\\ the\\ extent\\ of\\ the\\ tumor\\.\\ \ \(0\)\
\-\ at\\ imaging\\ studies\\,\\ parosteal\\ sarcoma\\ \\ should\\ be\\ differentiated\\ from\\ myositis\\ ossificans\\,\\ sessile\\ osteochondroma\\,\\ periosteal\\ osteosarcoma\\,\\ and\\ ossifying\\ soft\\ tissue\\ tumors\\ arising\\ from\\ the\\ cortical\\ bone\\ surface\\.\ \(0\)\
\-\ myositis\\ ossificans\\ may\\ present\\ with\\ a\\ history\\ of\\ trauma\\ followed\\ by\\ rapid\\ development\\ of\\ a\\ soft\\ tissue\\ mass\\,\\ which\\ ossifies\\ at\\ the\\ periphery\\ initially\\ as\\ opposed\\ to\\ the\\ base\\.\ \(0\)\
\-\ sessile\\ osteochondroma\\ should\\ show\\ a\\ continuity\\ between\\ both\\ the\\ cortex\\ and\\ spongiosa\\ of\\ the\\ underlying\\ normal\\ bone\\.\\ \\ \ \(0\)\
\-\ periosteal\\ osteosarcoma\\ is\\ smaller\\ and\\ has\\ a\\ distinctive\\ spiculated\\ periosteal\\ reaction\\.\\ \\ \ \(0\)\
\-\ other\\ ossifying\\ masses\\ from\\ the\\ cortex\\ such\\ as\\ chondrosarcomas\\,\\ high\\-grade\\ osteosarcomas\\ and\\ osteoma\\ should\\ be\\ differentiated\\ by\\ their\\ combined\\ imaging\\,\\ clinical\\ and\\ histologic\\ findings\\.\\ \\ \ \(0\)\
\-\ the\\ treatment\\ of\\ parosteal\\ sarcoma\\ is\\ surgical\\ resection\\ without\\ adjuvant\\ chemotherapy\\.\ \(0\)\
\-\ parosteal\\ osteosarcomas\\ are\\ uncommon\\ malignant\\ bone\\ tumors\\ that\\ account\\ for\\ approximately\\ 3\\%\\ of\\ osteosarcomas\\.\\ \\ they\\ occur\\ in\\ adults\\ between\\ the\\ 2nd\\ and\\ 5th\\ decades\\ and\\ affect\\ both\\ males\\ and\\ females\\ equally\\.\\ \\ they\\ typically\\ present\\ with\\ insidious\\ onset\\ of\\ symptoms\\ of\\ pain\\,\\ swelling\\,\\ and\\ a\\ palpable\\ mass\\.\\ \\ the\\ large\\ size\\ of\\ many\\ of\\ these\\ tumors\\ on\\ presentation\\ is\\ due\\ to\\ a\\ delay\\ in\\ the\\ patient\\ consulting\\ a\\ physician\\ because\\ of\\ the\\ slow\\ onset\\ of\\ symptoms\\.\\ \\ parosteal\\ osteosarcomas\\ occur\\ nearly\\ exclusively\\ in\\ long\\ tubular\\ bones\\,\\ most\\ commonly\\ in\\ the\\ femur\\,\\ which\\ accounts\\ for\\ 65\\%\\ of\\ cases\\.\\ \\ in\\ this\\ bone\\,\\ they\\ typically\\ arise\\ on\\ the\\ posterior\\ surface\\ of\\ the\\ distal\\ femur\\ in\\ the\\ metaphyseal\\ region\\.\ \(0\)\
\-\ on\\ plain\\ radiographs\\,\\ parosteal\\ osteosarcomas\\ appear\\ as\\ a\\ large\\ radiodense\\,\\ oval\\ or\\ spheroid\\ mass\\ with\\ smooth\\ lobulated\\ or\\ irregular\\ margins\\,\\ attached\\ in\\ a\\ sessile\\ manner\\ to\\ a\\ possibly\\ thickened\\ external\\ cortex\\.\\ \\ a\\ thin\\ radiolucent\\ line\\ or\\ cleavage\\ plane\\ separates\\ the\\ tumor\\ from\\ the\\ underlying\\ bone\\ and\\ is\\ caused\\ by\\ a\\ 2\\-3mm\\ fibrous\\ membrane\\.\\ \\ as\\ the\\ lesion\\ grows\\ in\\ size\\,\\ the\\ radiolucent\\ line\\ is\\ obscured\\ by\\ the\\ tumor\\ growing\\ circumferentially\\ around\\ the\\ bone\\.\ \(0\)\
\-\ ossification\\ of\\ the\\ tumor\\ extends\\ from\\ the\\ base\\ of\\ the\\ lesion\\ to\\ its\\ periphery\\ in\\ contrast\\ to\\ myositis\\ ossificans\\,\\ which\\,\\ when\\ mature\\,\\ shows\\ a\\ zonal\\ pattern\\ with\\ peripheral\\ ossification\\.\ \(0\)\
\-\ on\\ ct\\ images\\,\\ foci\\ of\\ radiolucencies\\ in\\ the\\ superficial\\ parts\\ of\\ the\\ tumor\\ may\\ represent\\ low\\-grade\\ malignant\\ cartilaginous\\,\\ fibrous\\ tissue\\,\\ or\\ entrapped\\ fat\\ and\\ trabeculae\\,\\ whereas\\,\\ more\\ central\\ radiolucencies\\ may\\ correlate\\ with\\ high\\-grade\\ dedifferentiated\\ tumor\\.\ \(0\)\
\-\ mri\\ should\\ be\\ done\\ to\\ evaluate\\ the\\ extent\\ of\\ the\\ tumor\\.\\ \ \(0\)\
\-\ at\\ imaging\\ studies\\,\\ parosteal\\ sarcoma\\ \\ should\\ be\\ differentiated\\ from\\ myositis\\ ossificans\\,\\ sessile\\ osteochondroma\\,\\ periosteal\\ osteosarcoma\\,\\ and\\ ossifying\\ soft\\ tissue\\ tumors\\ arising\\ from\\ the\\ cortical\\ bone\\ surface\\.\ \(0\)\
\-\ myositis\\ ossificans\\ may\\ present\\ with\\ a\\ history\\ of\\ trauma\\ followed\\ by\\ rapid\\ development\\ of\\ a\\ soft\\ tissue\\ mass\\,\\ which\\ ossifies\\ at\\ the\\ periphery\\ initially\\ as\\ opposed\\ to\\ the\\ base\\.\ \(0\)\
\-\ sessile\\ osteochondroma\\ should\\ show\\ a\\ continuity\\ between\\ both\\ the\\ cortex\\ and\\ spongiosa\\ of\\ the\\ underlying\\ normal\\ bone\\.\\ \\ \ \(0\)\
\-\ periosteal\\ osteosarcoma\\ is\\ smaller\\ and\\ has\\ a\\ distinctive\\ spiculated\\ periosteal\\ reaction\\.\\ \\ \ \(0\)\
\-\ other\\ ossifying\\ masses\\ from\\ the\\ cortex\\ such\\ as\\ chondrosarcomas\\,\\ high\\-grade\\ osteosarcomas\\ and\\ osteoma\\ should\\ be\\ differentiated\\ by\\ their\\ combined\\ imaging\\,\\ clinical\\ and\\ histologic\\ findings\\.\\ \\ \ \(0\)\
\-\ the\\ treatment\\ of\\ parosteal\\ sarcoma\\ is\\ surgical\\ resection\\ without\\ adjuvant\\ chemotherapy\\.\ \(0\)\
\-\ the\\ major\\ prognostic\\ factors\\ are\\ the\\ grade\\ of\\ the\\ lesion\\ and\\ presence\\ of\\ intramedullary\\ involvement\\.\\ \\ low\\-grade\\ lesions\\ have\\ a\\ better\\ prognosis\\ than\\ high\\-grade\\ lesions\\.\\ \\ intramedulary\\ invasion\\ has\\ a\\ poor\\ prognosis\\.\\ \\ it\\ is\\ extremely\\ rare\\ for\\ distant\\ metastasis\\ to\\ occur\\ without\\ intramedulary\\ involvement\\.\ \(0\)\
\-\ another\\ poor\\ prognostic\\ factor\\ is\\ progressive\\ dedifferentiation\\ from\\ low\\-grade\\ to\\ high\\-grade\\ osteosarcoma\\.\\ \\ this\\ has\\ been\\ reported\\ to\\ develop\\ with\\ recurrence\\ after\\ surgical\\ resection\\ or\\ with\\ undetected\\ conventional\\ parosteal\\ osteosarcoma\\ over\\ a\\ long\\ period\\ of\\ time\\.\\ \\ the\\ incidence\\ of\\ dedifferentiation\\ of\\ parosteal\\ osteosarcomas\\ is\\ reported\\ can\\ be\\ as\\ frequent\\ as\\ 20\\-25\\%\\ of\\ patients\\.\\ \\ the\\ posterior\\ aspect\\ of\\ the\\ femur\\ is\\ the\\ usual\\ site\\ for\\ dedifferentiated\\ osteosarcoma\\.\ \(0\)\
\-\ as\\ mentioned\\ earlier\\,\\ parosteal\\ osteosarcoma\\ is\\ the\\ most\\ favorable\\ osteosarcoma\\ variant\\.\\ \\ patients\\ with\\ conventional\\ parosteal\\ osteosarcoma\\ typically\\ do\\ well\\ after\\ resection\\ with\\ a\\ long\\-term\\ survival\\ rate\\ of\\ 80\\-90\\%\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ parosteal\\:\\ 0\\.08868229611821882\ \(0\)\
\-\ osteosarcomas\\:\\ 0\\.0819009313037428\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.04881665323436926\ \(0\)\
\-\ sessile\\:\\ 0\\.035726780331154576\ \(0\)\
\-\ ossificans\\:\\ 0\\.033844030231636214\ \(0\)\
\-\ myositis\\:\\ 0\\.03201034400011014\ \(0\)\
\-\ high\\-grade\\:\\ 0\\.02949215954600933\ \(0\)\
\-\ cortex\\:\\ 0\\.027794060914499766\ \(0\)\
\-\ radiolucencies\\:\\ 0\\.027440443389887003\ \(0\)\
\-\ periosteal\\:\\ 0\\.023964029919071955\ \(0\)\
\-\ bone\\:\\ 0\\.023314738901164114\ \(0\)\
\-\ ossifying\\:\\ 0\\.022757016494211697\ \(0\)\
\-\ radiolucent\\:\\ 0\\.022213557273974175\ \(0\)\
\-\ tumor\\:\\ 0\\.02187417223052411\ \(0\)\
\-\ osteochondroma\\:\\ 0\\.021443618267242948\ \(0\)\
\-\ dedifferentiated\\:\\ 0\\.018824047456537013\ \(0\)\
\-\ femur\\:\\ 0\\.01870720157717858\ \(0\)\
\-\ should\\:\\ 0\\.018406814472221623\ \(0\)\
\-\ ossification\\:\\ 0\\.01832002368871745\ \(0\)\
\-\ low\\-grade\\:\\ 0\\.017675673937535098\ \(0\)\
\-\ separates\\:\\ 0\\.017406102047916854\ \(0\)\
\-\ tumors\\:\\ 0\\.016265454515222134\ \(0\)\
\-\ periphery\\:\\ 0\\.016123199851797124\ \(0\)\
\-\ mass\\:\\ 0\\.016060283877669793\ \(0\)\
\-\ surface\\:\\ 0\\.015929448087192787\ \(0\)\
\-\ they\\:\\ 0\\.015602767532874862\ \(0\)\
\-\ differentiated\\:\\ 0\\.015429132371341686\ \(0\)\
\-\ posterior\\:\\ 0\\.014971914643853073\ \(0\)\
\-\ dedifferentiation\\:\\ 0\\.014891078418862329\ \(0\)\
\-\ line\\:\\ 0\\.014831982752987428\ \(0\)\
\-\ base\\:\\ 0\\.01413622585655138\ \(0\)\
\-\ from\\:\\ 0\\.013905121850510778\ \(0\)\
\-\ spheroid\\:\\ 0\\.013720221694943502\ \(0\)\
\-\ spongiosa\\:\\ 0\\.013720221694943502\ \(0\)\
\-\ occur\\:\\ 0\\.013539048263435553\ \(0\)\
\-\ \\,\\:\\ 0\\.013489775224256718\ \(0\)\
\-\ intensity\\:\\ 0\\.01304337278876394\ \(0\)\
\-\ zonal\\:\\ 0\\.013035314417733765\ \(0\)\
\-\ entrapped\\:\\ 0\\.013035314417733765\ \(0\)\
\-\ intramedulary\\:\\ 0\\.013035314417733765\ \(0\)\
\-\ sarcoma\\:\\ 0\\.012854334898210279\ \(0\)\
\-\ typically\\:\\ 0\\.012738284499602924\ \(0\)\
\-\ cleavage\\:\\ 0\\.012549364971024676\ \(0\)\
\-\ ossifies\\:\\ 0\\.012549364971024676\ \(0\)\
\-\ underlying\\:\\ 0\\.012372387937394322\ \(0\)\
\-\ 2\\-3mm\\:\\ 0\\.01217243329650743\ \(0\)\
\-\ as\\:\\ 0\\.012008743720300174\ \(0\)\
\-\ tissue\\:\\ 0\\.011974618512810942\ \(0\)\
\-\ consulting\\:\\ 0\\.011864457693814938\ \(0\)\
\-\ chondrosarcomas\\:\\ 0\\.011864457693814938\ \(0\)\
\-\ fibrous\\:\\ 0\\.011669683304922544\ \(0\)\
\-\ signal\\:\\ 0\\.011417606403409351\ \(0\)\
\-\ radiodense\\:\\ 0\\.011378508247105849\ \(0\)\
\-\ circumferentially\\:\\ 0\\.011378508247105849\ \(0\)\
\-\ distinctive\\:\\ 0\\.011378508247105849\ \(0\)\
\-\ a\\:\\ 0\\.010718913562664899\ \(0\)\
\-\ grows\\:\\ 0\\.01069360096989611\ \(0\)\
\-\ cortical\\:\\ 0\\.010523901522215582\ \(0\)\
\-\ malignant\\:\\ 0\\.010434698231011152\ \(0\)\
\-\ invasion\\:\\ 0\\.010426616701454599\ \(0\)\
\-\ \\%\\:\\ 0\\.010101289020334499\ \(0\)\
\-\ parts\\:\\ 0\\.010008693692686376\ \(0\)\
\-\ trabeculae\\:\\ 0\\.010008693692686376\ \(0\)\
\-\ shows\\:\\ 0\\.009921341637368577\ \(0\)\
\-\ insidious\\:\\ 0\\.009917363927027125\ \(0\)\
\-\ obscured\\:\\ 0\\.009917363927027125\ \(0\)\
\-\ margins\\:\\ 0\\.009833727595023158\ \(0\)\
\-\ exclusively\\:\\ 0\\.009830719848669777\ \(0\)\
\-\ manner\\:\\ 0\\.009830719848669777\ \(0\)\
\-\ size\\:\\ 0\\.009678634700603959\ \(0\)\
\-\ adjuvant\\:\\ 0\\.009669722923324632\ \(0\)\
\-\ prognostic\\:\\ 0\\.009669722923324632\ \(0\)\
\-\ by\\:\\ 0\\.009613992589492398\ \(0\)\
\-\ equally\\:\\ 0\\.009594635486549576\ \(0\)\
\-\ may\\:\\ 0\\.009498285653199953\ \(0\)\
\-\ opposed\\:\\ 0\\.009323786415476638\ \(0\)\
\-\ decades\\:\\ 0\\.009262354584106916\ \(0\)\
\-\ cartilaginous\\:\\ 0\\.009262354584106916\ \(0\)\
\-\ between\\:\\ 0\\.009150322757514338\ \(0\)\
\-\ histologic\\:\\ 0\\.009145812571460039\ \(0\)\
\-\ onset\\:\\ 0\\.009112909547044426\ \(0\)\
\-\ accounts\\:\\ 0\\.009090424357232015\ \(0\)\
\-\ resection\\:\\ 0\\.00900309343081155\ \(0\)\
\-\ correlate\\:\\ 0\\.008984815646114894\ \(0\)\
\-\ continuity\\:\\ 0\\.008791554917774112\ \(0\)\
\-\ spiculated\\:\\ 0\\.008791554917774112\ \(0\)\
\-\ soft\\:\\ 0\\.008787697483080871\ \(0\)\
\-\ oval\\:\\ 0\\.008746507203108298\ \(0\)\
\-\ mature\\:\\ 0\\.00870262969229198\ \(0\)\
\-\ metaphyseal\\:\\ 0\\.008618152630510457\ \(0\)\
\-\ attached\\:\\ 0\\.008577447306897178\ \(0\)\
\-\ whereas\\:\\ 0\\.008577447306897178\ \(0\)\
\-\ osteoma\\:\\ 0\\.008577447306897178\ \(0\)\
\-\ membrane\\:\\ 0\\.008460905294250302\ \(0\)\
\-\ distant\\:\\ 0\\.00842377876263075\ \(0\)\
\-\ affect\\:\\ 0\\.00831705764502681\ \(0\)\
\-\ males\\:\\ 0\\.00831705764502681\ \(0\)\
\-\ conventional\\:\\ 0\\.008184504240564825\ \(0\)\
\-\ account\\:\\ 0\\.00815292969155781\ \(0\)\
\-\ metastasis\\:\\ 0\\.00810493410380049\ \(0\)\
\-\ studies\\:\\ 0\\.008086573271399899\ \(0\)\
\-\ which\\:\\ 0\\.008083502975891294\ \(0\)\
\-\ plane\\:\\ 0\\.008061599925898562\ \(0\)\
\-\ females\\:\\ 0\\.008032221982128513\ \(0\)\
\-\ growing\\:\\ 0\\.007974955847541213\ \(0\)\
\-\ combined\\:\\ 0\\.007974955847541213\ \(0\)\
\-\ nearly\\:\\ 0\\.007947034729380385\ \(0\)\
\-\ the\\:\\ 0\\.007939992702573104\ \(0\)\
\-\ large\\:\\ 0\\.007890804188475844\ \(0\)\
\-\ distal\\:\\ 0\\.007848914151844686\ \(0\)\
\-\ slow\\:\\ 0\\.007813958922196069\ \(0\)\
\-\ be\\:\\ 0\\.00779079143868877\ \(0\)\
\-\ superficial\\:\\ 0\\.007714566185670843\ \(0\)\
\-\ or\\:\\ 0\\.007612926301244399\ \(0\)\
\-\ in\\:\\ 0\\.007474106277825467\ \(0\)\
\-\ long\\:\\ 0\\.007465088287582915\ \(0\)\
\-\ 5th\\:\\ 0\\.007426820635422129\ \(0\)\
\-\ possibly\\:\\ 0\\.007386599945061118\ \(0\)\
\-\ both\\:\\ 0\\.007372297265831491\ \(0\)\
\-\ adults\\:\\ 0\\.007366843121136808\ \(0\)\
\-\ lesion\\:\\ 0\\.007350317677366785\ \(0\)\
\-\ on\\:\\ 0\\.007336733233433393\ \(0\)\
\-\ rapid\\:\\ 0\\.007290048570331476\ \(0\)\
\-\ lobulated\\:\\ 0\\.007252922038711923\ \(0\)\
\-\ 2nd\\:\\ 0\\.007198718804672226\ \(0\)\
\-\ symptoms\\:\\ 0\\.007194788773304524\ \(0\)\
\-\ delay\\:\\ 0\\.007163526090309317\ \(0\)\
\-\ extent\\:\\ 0\\.007163526090309317\ \(0\)\
\-\ arise\\:\\ 0\\.007146200921107983\ \(0\)\
\-\ is\\:\\ 0\\.007123616280211896\ \(0\)\
\-\ uncommon\\:\\ 0\\.007062144317123079\ \(0\)\
\-\ 65\\:\\ 0\\.007045823521664064\ \(0\)\
\-\ smaller\\:\\ 0\\.006997786468757756\ \(0\)\
\-\ 6\\.7cm\\:\\ 0\\.006860110847471751\ \(0\)\
\-\ 8\\.3cm\\:\\ 0\\.006860110847471751\ \(0\)\
\-\ radiographs\\:\\ 0\\.006857105171964864\ \(0\)\
\-\ prognosis\\:\\ 0\\.006846865691163416\ \(0\)\
\-\ physician\\:\\ 0\\.006804099123622387\ \(0\)\
\-\ imaging\\:\\ 0\\.006763762920458117\ \(0\)\
\-\ image\\:\\ 0\\.006763148225416219\ \(0\)\
\-\ tubular\\:\\ 0\\.006721683305768616\ \(0\)\
\-\ reaction\\:\\ 0\\.006555818396682106\ \(0\)\
\-\ present\\:\\ 0\\.006520299844363787\ \(0\)\
\-\ 7\\.3cm\\:\\ 0\\.006517657208866883\ \(0\)\
\-\ juxtaposed\\:\\ 0\\.006517657208866883\ \(0\)\
\-\ poor\\:\\ 0\\.006496123520929895\ \(0\)\
\-\ to\\:\\ 0\\.0064925894864643185\ \(0\)\
\-\ thickened\\:\\ 0\\.00647282399030095\ \(0\)\
\-\ represent\\:\\ 0\\.00633939761983029\ \(0\)\
\-\ smooth\\:\\ 0\\.006318149676913297\ \(0\)\
\-\ their\\:\\ 0\\.006318149676913297\ \(0\)\
\-\ development\\:\\ 0\\.006286770647229284\ \(0\)\
\-\ juxtacortical\\:\\ 0\\.006274682485512338\ \(0\)\
\-\ extends\\:\\ 0\\.006255963911503303\ \(0\)\
\-\ foci\\:\\ 0\\.006195986397217982\ \(0\)\
\-\ external\\:\\ 0\\.006138065664990563\ \(0\)\
\-\ region\\:\\ 0\\.00611554365009961\ \(0\)\
\-\ bones\\:\\ 0\\.00609127072825182\ \(0\)\
\-\ caused\\:\\ 0\\.006054746295797148\ \(0\)\
\-\ around\\:\\ 0\\.006010174074220806\ \(0\)\
\-\ done\\:\\ 0\\.0059839845699370805\ \(0\)\
\-\ arising\\:\\ 0\\.005975344197189158\ \(0\)\
\-\ many\\:\\ 0\\.005932793101194971\ \(0\)\
\-\ thin\\:\\ 0\\.005932793101194971\ \(0\)\
\-\ appear\\:\\ 0\\.0059077676184498005\ \(0\)\
\-\ initially\\:\\ 0\\.005874966797745237\ \(0\)\
\-\ evaluate\\:\\ 0\\.005834841652461272\ \(0\)\
\-\ undetected\\:\\ 0\\.0058020340159722844\ \(0\)\
\-\ irregular\\:\\ 0\\.0057573423184229386\ \(0\)\
\-\ emanating\\:\\ 0\\.0055897752083026\ \(0\)\
\-\ pattern\\:\\ 0\\.005517639086269051\ \(0\)\
\-\ 20\\-25\\:\\ 0\\.005500788286294301\ \(0\)\
\-\ 80\\-90\\:\\ 0\\.005500788286294301\ \(0\)\
\-\ femoral\\:\\ 0\\.0054915507037902106\ \(0\)\
\-\ commonly\\:\\ 0\\.005446843654485881\ \(0\)\
\-\ its\\:\\ 0\\.005446843654485881\ \(0\)\
\-\ has\\:\\ 0\\.00542128368410229\ \(0\)\
\-\ heterogenously\\:\\ 0\\.00542028982362173\ \(0\)\
\-\ involvement\\:\\ 0\\.00529043691997942\ \(0\)\
\-\ correlating\\:\\ 0\\.005279196846710271\ \(0\)\
\-\ reported\\:\\ 0\\.005261950761107791\ \(0\)\
\-\ knee\\:\\ 0\\.005233937031351819\ \(0\)\
\-\ peripheral\\:\\ 0\\.005222860341240063\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.0051738949073325425\ \(0\)\
\-\ palpable\\:\\ 0\\.005115913923310457\ \(0\)\
\-\ without\\:\\ 0\\.005098006333677771\ \(0\)\
\-\ because\\:\\ 0\\.005049862021260216\ \(0\)\
\-\ most\\:\\ 0\\.004998737690189382\ \(0\)\
\-\ mri\\:\\ 0\\.004974516524276908\ \(0\)\
\-\ presentation\\:\\ 0\\.004971960531234936\ \(0\)\
\-\ at\\:\\ 0\\.004889202503511964\ \(0\)\
\-\ masses\\:\\ 0\\.004879379050669067\ \(0\)\
\-\ followed\\:\\ 0\\.004839317350301979\ \(0\)\
\-\ swelling\\:\\ 0\\.0048088021351032646\ \(0\)\
\-\ cases\\:\\ 0\\.0048088021351032646\ \(0\)\
\-\ x\\:\\ 0\\.004761936377276144\ \(0\)\
\-\ central\\:\\ 0\\.004749377291993174\ \(0\)\
\-\ of\\:\\ 0\\.004723127059377909\ \(0\)\
\-\ enzymes\\:\\ 0\\.0046937684847508584\ \(0\)\
\-\ favorable\\:\\ 0\\.0046937684847508584\ \(0\)\
\-\ plain\\:\\ 0\\.004687945460623454\ \(0\)\
\-\ mr\\:\\ 0\\.004586485594504112\ \(0\)\
\-\ adjacent\\:\\ 0\\.004563912574551127\ \(0\)\
\-\ surgical\\:\\ 0\\.004551237593542535\ \(0\)\
\-\ such\\:\\ 0\\.004512386469325764\ \(0\)\
\-\ intramedullary\\:\\ 0\\.004467194171748595\ \(0\)\
\-\ approximately\\:\\ 0\\.0044659084908033496\ \(0\)\
\-\ clinical\\:\\ 0\\.004441401689300683\ \(0\)\
\-\ show\\:\\ 0\\.00443100664610072\ \(0\)\
\-\ fat\\:\\ 0\\.004390054599462219\ \(0\)\
\-\ popliteal\\:\\ 0\\.004373253601554149\ \(0\)\
\-\ mentioned\\:\\ 0\\.004309076315255228\ \(0\)\
\-\ panel\\:\\ 0\\.0042494330997029026\ \(0\)\
\-\ usual\\:\\ 0\\.004211889381315375\ \(0\)\
\-\ when\\:\\ 0\\.0041340054689459555\ \(0\)\
\-\ extremely\\:\\ 0\\.004108340122791445\ \(0\)\
\-\ t2\\:\\ 0\\.004085454001267487\ \(0\)\
\-\ low\\:\\ 0\\.004013797386598648\ \(0\)\
\-\ long\\-term\\:\\ 0\\.003987477923770607\ \(0\)\
\-\ t1\\-weighted\\:\\ 0\\.003959783816656594\ \(0\)\
\-\ high\\:\\ 0\\.0039502467247919185\ \(0\)\
\-\ trauma\\:\\ 0\\.003947649969185691\ \(0\)\
\-\ diaphysis\\:\\ 0\\.003881765809789182\ \(0\)\
\-\ survival\\:\\ 0\\.003869435742710506\ \(0\)\
\-\ lesions\\:\\ 0\\.003864122476932344\ \(0\)\
\-\ due\\:\\ 0\\.00385181951512304\ \(0\)\
\-\ these\\:\\ 0\\.0037564944120909464\ \(0\)\
\-\ patients\\:\\ 0\\.003735767904334503\ \(0\)\
\-\ better\\:\\ 0\\.003723647953295815\ \(0\)\
\-\ well\\-defined\\:\\ 0\\.0037134103177110644\ \(0\)\
\-\ heterogenous\\:\\ 0\\.003703295291489176\ \(0\)\
\-\ for\\:\\ 0\\.0036948048073110564\ \(0\)\
\-\ factor\\:\\ 0\\.003683421560568404\ \(0\)\
\-\ surgically\\:\\ 0\\.003654461194454695\ \(0\)\
\-\ t2\\-weighted\\:\\ 0\\.003654461194454695\ \(0\)\
\-\ and\\:\\ 0\\.0036488311972746987\ \(0\)\
\-\ more\\:\\ 0\\.003610095117081362\ \(0\)\
\-\ frequent\\:\\ 0\\.0036082969946760936\ \(0\)\
\-\ develop\\:\\ 0\\.003599359402336113\ \(0\)\
\-\ resected\\:\\ 0\\.0035731004605539917\ \(0\)\
\-\ metabolic\\:\\ 0\\.0035645258224931663\ \(0\)\
\-\ earlier\\:\\ 0\\.0035645258224931663\ \(0\)\
\-\ firm\\:\\ 0\\.0035393121711843134\ \(0\)\
\-\ center\\:\\ 0\\.0035393121711843134\ \(0\)\
\-\ vessel\\:\\ 0\\.003437995182097338\ \(0\)\
\-\ variant\\:\\ 0\\.003437995182097338\ \(0\)\
\-\ gadolinium\\:\\ 0\\.003423432845581708\ \(0\)\
\-\ visible\\:\\ 0\\.00341624476309192\ \(0\)\
\-\ normal\\:\\ 0\\.0033942883140179927\ \(0\)\
\-\ 3\\:\\ 0\\.0033800262275448306\ \(0\)\
\-\ major\\:\\ 0\\.0033743554546971804\ \(0\)\
\-\ period\\:\\ 0\\.0033743554546971804\ \(0\)\
\-\ other\\:\\ 0\\.0033270921430784608\ \(0\)\
\-\ incidence\\:\\ 0\\.0033088501892023538\ \(0\)\
\-\ well\\:\\ 0\\.003265339447582181\ \(0\)\
\-\ it\\:\\ 0\\.0032446763252246907\ \(0\)\
\-\ factors\\:\\ 0\\.0032422167918462197\ \(0\)\
\-\ contrast\\:\\ 0\\.0032310400114998403\ \(0\)\
\-\ cbc\\:\\ 0\\.003224920734968229\ \(0\)\
\-\ recurrence\\:\\ 0\\.0031485828452146236\ \(0\)\
\-\ do\\:\\ 0\\.003133085261879998\ \(0\)\
\-\ another\\:\\ 0\\.0031029179623849987\ \(0\)\
\-\ findings\\:\\ 0\\.0030723596888343916\ \(0\)\
\-\ site\\:\\ 0\\.003050263291291979\ \(0\)\
\-\ defined\\:\\ 0\\.0030410326573965477\ \(0\)\
\-\ after\\:\\ 0\\.0029864885179209503\ \(0\)\
\-\ are\\:\\ 0\\.0029515385283689233\ \(0\)\
\-\ tender\\:\\ 0\\.00292940109227114\ \(0\)\
\-\ treatment\\:\\ 0\\.0029216502695960933\ \(0\)\
\-\ no\\:\\ 0\\.0029069059145398718\ \(0\)\
\-\ progressive\\:\\ 0\\.002852566820137925\ \(0\)\
\-\ necrosis\\:\\ 0\\.002848902629598568\ \(0\)\
\-\ rate\\:\\ 0\\.0028131093669559485\ \(0\)\
\-\ 24\\:\\ 0\\.002806129206609755\ \(0\)\
\-\ rare\\:\\ 0\\.002802660640771365\ \(0\)\
\-\ images\\:\\ 0\\.0027690268445090442\ \(0\)\
\-\ grade\\:\\ 0\\.002749017561613995\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.0026538810445903764\ \(0\)\
\-\ presence\\:\\ 0\\.002619751366940143\ \(0\)\
\-\ that\\:\\ 0\\.0024932106901331477\ \(0\)\
\-\ liver\\:\\ 0\\.0024883627625276383\ \(0\)\
\-\ this\\:\\ 0\\.002435313885086486\ \(0\)\
\-\ study\\:\\ 0\\.002374688645996587\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.0023480042157447145\ \(0\)\
\-\ radiograph\\:\\ 0\\.002298943119866016\ \(0\)\
\-\ further\\:\\ 0\\.0022951386332772453\ \(0\)\
\-\ right\\:\\ 0\\.0022845398034892317\ \(0\)\
\-\ post\\:\\ 0\\.0022726647238786265\ \(0\)\
\-\ aspect\\:\\ 0\\.0022671384581785113\ \(0\)\
\-\ with\\:\\ 0\\.0020752429880808144\ \(0\)\
\-\ time\\:\\ 0\\.0020385145500332034\ \(0\)\
\-\ ct\\:\\ 0\\.0020190940091081807\ \(0\)\
\-\ y\\/o\\:\\ 0\\.0019988420859963184\ \(0\)\
\-\ history\\:\\ 0\\.001993605638018722\ \(0\)\
\-\ been\\:\\ 0\\.001963509197182425\ \(0\)\
\-\ \\:\\:\\ 0\\.0019092479999842317\ \(0\)\
\-\ evidence\\:\\ 0\\.0018922656954112145\ \(0\)\
\-\ than\\:\\ 0\\.0018910885598971909\ \(0\)\
\-\ over\\:\\ 0\\.0018375359714019955\ \(0\)\
\-\ consistent\\:\\ 0\\.001769677591918246\ \(0\)\
\-\ pain\\:\\ 0\\.0017628516343424574\ \(0\)\
\-\ \\.\\:\\ 0\\.0017389975453091925\ \(0\)\
\-\ can\\:\\ 0\\.0016370121220177954\ \(0\)\
\-\ have\\:\\ 0\\.0015628699986191654\ \(0\)\
\-\ lateral\\:\\ 0\\.0015596858493450595\ \(0\)\
\-\ patient\\:\\ 0\\.0014469458292506554\ \(0\)\
\-\ male\\:\\ 0\\.001305072244837393\ \(0\)\
\-\ was\\:\\ 0\\.0008346938532210193\ \(0\)\
